NCT03669250View on ClinicalTrials.gov

CVN058 Effect on Mismatch Negativity in Schizophrenics

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

March 6, 2020

Study Completion Date

March 6, 2020

Conditions
Schizophrenia
Interventions
DRUG

CVN058

CVN058 will be given at two doses, a low does and a high dose

OTHER

Placebo comparator

inactive placebo

Trial Locations (3)

10029

Icahn School of Medicine at Mount Sinai, New York

10032

New York State Psychiatric Institute, New York

10962

Nathan Kline Institute, New York

All Listed Sponsors
lead

Cerevance Alpha, Inc.

INDUSTRY

NCT03669250 - CVN058 Effect on Mismatch Negativity in Schizophrenics | Biotech Hunter | Biotech Hunter